Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 232

Sort by

Sort Order Select

Journal Articles

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl

Blood (2021) 137 (19): 2634–2645.

https://doi.org/10.1182/blood.2020007512

Published: 2021

Includes: Supplemental data

Journal Articles

Hepatosplenic T Cell Lymphoma Case Report Presented with Hemphagocytosis Lymphohistiocytosis

Mohamed Abu Haleeqa, MBBS, Fatemah Alshehi, MBBS, Gannat Alghamrawi, MBBS, Lois Richard

Blood (2019) 134 (Supplement_1): 5363.

https://doi.org/10.1182/blood-2019-126445

Published: 2019

Journal Articles

Telomere Elongation and Clinical Improvement in Telomeropathy Patients: A Prospective Clinical Trial of Nandrolone in Telomeropathies

Diego V Clé, MD PhD, Luiz Fernando Catto, MD, Luiz Guilherme Darrigo, PhD, Elvis Valera, Fernanda Gutierrez-Rodrigues, PhD, Flavia S. Donaires, PhD, André Pinto, Renan C. Albino, Bárbara Santana, Jose Baddini-Martinez, MD PhD, Rodrigo T. Calado, MD PhD

Blood (2019) 134 (Supplement_1): 2501.

https://doi.org/10.1182/blood-2019-130844

Published: 2019

Journal Articles

Early Hyperbilirubinemia Is an Independent Predictor of Outcome after Allogeneic Stem Cell Transplantation and Correlates with Markers of Endothelial Cell Dysfunction

Thomas Luft, MD PhD, Hao Dai, Aleksandar Radujkovic, MD, David Schult, Joshua Majer-Lauterbach, Olga Blau, MD PhD, Lars Bullinger, Sihe Jiang, Carsten Müller-Tidow, MD, Peter Dreger, Olaf Penack, MD

Blood (2019) 134 (Supplement_1): 4487.

https://doi.org/10.1182/blood-2019-124284

Published: 2019

Journal Articles

One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B

Steven Pipe, MD, Adam Giermasz, MD PhD, Giancarlo Castaman, MD, Nigel S. Key, MBChB, FRCP, Susan U Lattimore, Frank Leebeek, MD PhD, Wolfgang Miesbach, MD PhD, Michael Recht, MD PhD, Esteban Gomez, MD, Alison Long, Robert Gut, Annette von Drygalski, MD PharmD

Blood (2019) 134 (Supplement_1): 3348.

https://doi.org/10.1182/blood-2019-128765

Published: 2019

Journal Articles

Safety Profile of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor: A Meta-Analysis of Randomized Controlled Trials

Apoorva Krishna Chandar, MDMPH, Omar Ali Alaber, MD, Muhammad Zain Farooq, MD MBBS, Basma Ali Dahash, MD, Ankit Mangla, MBBS, MD

Blood (2019) 134 (Supplement_1): 4890.

https://doi.org/10.1182/blood-2019-127782

Published: 2019

Journal Articles

First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A

Steven Pipe, MD, Michael Becka, Elke Detering, Konstantina Vanevski, Toshko Lissitchkov

Blood (2019) 134 (Supplement_1): 4630.

https://doi.org/10.1182/blood-2019-125764

Published: 2019

Journal Articles

Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Comparison of Deferasirox Formulations for Treatment Tailoring

Andrea Piolatto, MS, Carmen Gaglioti, MD, Filomena Longo, MD, Silvia De Francia, PhD, Sarah Allegra, PhD, Paola Berchialla, PhD, Antonio Piga

Blood (2019) 134 (Supplement_1): 3547.

https://doi.org/10.1182/blood-2019-122030

Published: 2019

Journal Articles

Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE ® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Marion Subklewe, MD, Anthony Stein, MD, Roland B. Walter, MD PhD MS, Ravi Bhatia, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, David Ritchie, MD PhD, Veit Bücklein, MD, Pankit Vachhani, MD, Tian Dai, PhD, Antreas Hindoyan, PhD, Suresh Agarwal, PhD, Abraham Anderson, Sophia Khaldoyanidi, MD PhD, Farhad Ravandi, MD

Blood (2019) 134 (Supplement_1): 833.

https://doi.org/10.1182/blood-2019-127977

Published: 2019

Journal Articles

Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience

Blood (2019) 134 (Supplement_1): 839.

https://doi.org/10.1182/blood-2019-127488

Published: 2019

Journal Articles

Safety and Efficacy of Long Term Suppression of PI3Kinase Pathway By Small Molecule PI3K-Delta Inhibitor, Leniolisib in Apds (Activated PI3Kδ Syndrome)

V. Koneti Rao, MD FRCPA, Sharon Webster, BSN, Virgil A.S.H. Dalm, MD, Anna Sediva, MD, P. Martin van Hagen, H. Michael Do, MD, Les Folio, MD, Maciej Cabanski, Marie-Anne Valentin, Stefan de Buck, Christoph Kalis, Anke Hasselberg, Christoph Burkhart, Klaus Kucher, MD, Birgitte Sloth, Gulbu Uzel, MD

Blood (2018) 132 (Supplement 1): 3706.

https://doi.org/10.1182/blood-2018-99-113426

Published: 2018

Journal Articles

Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience

Blood (2018) 132 (Supplement 1): 91.

https://doi.org/10.1182/blood-2018-99-114152

Published: 2018

Journal Articles

A Single Intravenous Infusion of FLT180a Results in Factor IX Activity Levels of More Than 40% and Has the Potential to Provide a Functional Cure for Patients with Haemophilia B

Pratima Chowdary, MD, Susie Shapiro, MD, Andrew M. Davidoff, MD, Ulrike Reiss, MD, Rebecca Alade, PhD, Geoff Brooks, BSc, Allison Dane, PhD, Jenny McIntosh, PhD, Gerard Short, MBBS, Edward Tuddenham, MD, Amit C Nathwani, MD PhD

Blood (2018) 132 (Supplement 1): 631.

https://doi.org/10.1182/blood-2018-99-118050

Published: 2018

Journal Articles

MP0250 Combined with Bortezomib and Dexamethasone in Multiple Myeloma Patients Previoulsy Exposed to Proteasome Inhibitors and Immunomodulatory Drugs

Stefan Knop, Hartmut Goldschmidt, MD, Marc S Raab, MD PhD, Monika Szarejko, Artur Jurczyszyn, MD, Jan Dürig, Sara Bringhen, Barbara Gamberi, MD, Angelo Vacca, Jorge Castellano Acosta, MD, Guy Lemaillet, PhD, Cedric Cortijo, PhD, Bansod Sudhir, Norbert Grząśko, MDPhD

Blood (2018) 132 (Supplement 1): 1980.

https://doi.org/10.1182/blood-2018-99-112859

Published: 2018

Journal Articles

Chronic HCV Infection and Autologous Stem Cell Transplantation for Multiple Myeloma

Blood (2018) 132 (Supplement 1): 5632.

https://doi.org/10.1182/blood-2018-99-115266

Published: 2018

Journal Articles

Non-Interventional Retrospective Multicenter Study Evaluating Real Word Idelalisib Use in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma Patients Enrolled in the French Early Access Program

Loic Ysebaert, MD PhD, Pierre Feugier, Gilles Andre Salles, MD PhD, Eric Durot, MD, Alexis Talbot, MD, Choquet Sylvain, MD, Denise Glorian Kergaravat, Alastair Simpson, Heribert Ramroth, Tarek Abdelhadi, Corinne Haioun, MD, Xavier Troussard, MD

Blood (2018) 132 (Supplement 1): 5924.

https://doi.org/10.1182/blood-2018-99-110766

Published: 2018

Journal Articles

The Challenge of Unexplained Splenomegalies: Preliminary Data of the French Prospective Multi-Center Splenomegaly Study (SMS)

Guillaume Denis, MD, Laurence Sanhes, MD, Jean-Marc Ziza, MD PhD, Frederic Bauduer, MD PhD, Marc G. Berger, MD PhD, Regis T. Costello, MD PhD, Kawkab Mehdi, Martin Michaud, MD, Geoffrey Urbanski, MD, Christian Rose, MD PhD

Blood (2018) 132 (Supplement 1): 4815.

https://doi.org/10.1182/blood-2018-99-113123

Published: 2018

Journal Articles

Adeno-Associated Mediated Gene Transfer for Hemophilia B:8 Year Follow up and Impact of Removing "Empty Viral Particles" on Safety and Efficacy of Gene Transfer

Amit C Nathwani, MD PhD, Ulrike Reiss, MD, Edward Tuddenham, MD, Pratima Chowdary, MD, Jenny McIntosh, PhD, Anne Riddell, Jun Pie, Johnny N Mahlangu, MD, Michael Recht, MD PhD, Yu-Min Shen, MD, Kathleen G. Halka, MD, Michael M Meagher, PhD, Arthur W. Nienhuis, MD, Andrew M. Davidoff, MD, Sarah Mangles, Chris L Morton, Zhou Junfang, Vlad Calin Radulescu, MD

Blood (2018) 132 (Supplement 1): 491.

https://doi.org/10.1182/blood-2018-99-118334

Published: 2018

Journal Articles

CD117-Amanitin Antibody Drug Conjugates Effectively Deplete Human and Non-Human Primate HSCs: Proof of Concept As a Targeted Strategy for Conditioning Patients for Bone Marrow Transplant

Bradley R Pearse, PhD, Sean M McDonough, MS, Jennifer L Proctor, BS, Rajiv Panwar, PhD, Ganapathy Sarma, PhD, Molly A McShea, MS, Lena Kien, BS, Junia Dushime, BS, Hillary L Adams, MS, Sharon L. Hyzy, MS, Melissa L. Brooks, BS, Rahul Palchaudhuri, PhD, Qing Li, PhD, Nathan M Kallen, BA, Pranoti Sawant, MS, Charlotte F McDonagh, PhD, Anthony E. Boitano, PhD, Michael P. Cooke, PhD

Blood (2018) 132 (Supplement 1): 3314.

https://doi.org/10.1182/blood-2018-99-114881

Published: 2018

Journal Articles

Blinatumomab Administered Concurrently with Oral Tyrosine Kinase Inhibitor Therapy Is a Well-Tolerated Consolidation Strategy and Eradicates Measurable Residual Disease in Adults with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Amber C. King, PharmD, BCOP, Jeremy Pappacena, PharmD, BCOP, Martin S. Tallman, MD, Jae H. Park, MD, Mark Blaine Geyer, MD

Blood (2018) 132 (Supplement 1): 1414.

https://doi.org/10.1182/blood-2018-99-113162

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Hepatosplenic T Cell Lymphoma Case Report Presented with Hemphagocytosis Lymphohistiocytosis

Telomere Elongation and Clinical Improvement in Telomeropathy Patients: A Prospective Clinical Trial of Nandrolone in Telomeropathies

Early Hyperbilirubinemia Is an Independent Predictor of Outcome after Allogeneic Stem Cell Transplantation and Correlates with Markers of Endothelial Cell Dysfunction

One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B

Safety Profile of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor: A Meta-Analysis of Randomized Controlled Trials

First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A

Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Comparison of Deferasirox Formulations for Treatment Tailoring

Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE ® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience

Safety and Efficacy of Long Term Suppression of PI3Kinase Pathway By Small Molecule PI3K-Delta Inhibitor, Leniolisib in Apds (Activated PI3Kδ Syndrome)

Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience

A Single Intravenous Infusion of FLT180a Results in Factor IX Activity Levels of More Than 40% and Has the Potential to Provide a Functional Cure for Patients with Haemophilia B

MP0250 Combined with Bortezomib and Dexamethasone in Multiple Myeloma Patients Previoulsy Exposed to Proteasome Inhibitors and Immunomodulatory Drugs

Chronic HCV Infection and Autologous Stem Cell Transplantation for Multiple Myeloma

Non-Interventional Retrospective Multicenter Study Evaluating Real Word Idelalisib Use in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma Patients Enrolled in the French Early Access Program

The Challenge of Unexplained Splenomegalies: Preliminary Data of the French Prospective Multi-Center Splenomegaly Study (SMS)

Adeno-Associated Mediated Gene Transfer for Hemophilia B:8 Year Follow up and Impact of Removing "Empty Viral Particles" on Safety and Efficacy of Gene Transfer

CD117-Amanitin Antibody Drug Conjugates Effectively Deplete Human and Non-Human Primate HSCs: Proof of Concept As a Targeted Strategy for Conditioning Patients for Bone Marrow Transplant

Blinatumomab Administered Concurrently with Oral Tyrosine Kinase Inhibitor Therapy Is a Well-Tolerated Consolidation Strategy and Eradicates Measurable Residual Disease in Adults with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only